natgillin/translations-raw huggingface dataset:
The exact way in which lacosamide works is still unclear but it seems to reduce the activity of sodium channels (pores on the surface of nerve cells) that allow electrical impulses to be transmitted between nerve cells.
Natančen način delovanja lakozamida doslej še ni bil pojasnjen, vendar se zdi, da zmanjšuje dejavnost natrijevih kanalov (por na površini živčnih celic), ki omogočajo, da se električni impulzi prenašajo med živčnimi celicami.
The exact way that Avonex works in MS is not yet known but interferon beta seems to calm the immune system down, and prevents relapses of MS.
Natančen način delovanja zdravila Avonex pri multipli sklerozi še ni popolnoma znan, toda vse kaže, da interferon beta pomirja imunski sistem in preprečuje ponovne napade multiple skleroze.
The exact way that Betaferon works in MS is not yet known but beta-interferon seems to reduce the activity of the immune system (the body’s natural defences) and prevents the relapses of MS.
Natančen način delovanja zdravila Betaferon pri multipli sklerozi še ni znan, vendar se zdi, da interferon beta pomirja imunski sistem (naravno obrambo telesa) in preprečuje recidive multiple skleroze.
The exact way that Extavia works in MS is not yet known but beta-interferon seems to calm down the immune system (the body’s natural defences) and prevents the relapses of MS.
Natančen način delovanja zdravila Extavia pri multipli sklerozi še ni znan, vendar se zdi, da interferon beta pomirja imunski sistem (naravno obrambo telesa) in preprečuje recidive multiple skleroze.
The exact way that Rebif works in MS is not yet fully understood but interferon beta seems to calm the immune system down and prevent relapses of MS.
Natančen način delovanja zdravila Rebif pri multipli sklerozi še ni popolnoma znan, toda vse kaže, da interferon beta pomirja imunski sistem in preprečuje ponovne zagone multiple skleroze.
The excess volume should be expelled before injecting
Presežni volumen je treba pred injiciranjem odstraniti.
The excess volume should be expelled before injecting.
Presežni volumen je treba pred injiciranjem odstraniti.
The excipient lactose may contain small amounts of milk proteins which may cause allergic reactions in those with severe hypersensitivity or allergy to milk protein.
Pomožna snov laktoza lahko vsebuje majhne količine mlečnih beljakovin, ki lahko povzročijo alergijske reakcije pri bolnikih s hudo preobčutljivostjo ali alergijo na mlečne beljakovine.
The excipient sunset yellow FCF (E110) included in the capsules shell may cause allergic reactions.
Ovoj kapsul vsebuje pomožno snov sončno rumeno FCF (E110), ki lahko povzroči alergijske reakcije.
The excipient sunset yellow FCF (E110) included in the capsules shell may cause allergic reactions.
Pomožna snov oranžni FCF (E 110), ki jo vsebuje ovoj kapsule, lahko povzroči alergično reakcijo.
The excipient sunset yellow FCF (E110) included in the capsules shell may cause allergic reactions.
Pomožna snov oranžno FCF (E 110), ki jo vsebuje ovoj kapsule, lahko povzroči alergično reakcijo.
The excipient sunset yellow FCF (E110) is also included in the capsules shell of Temozolomide Teva 20 mg hard capsules and may cause allergic reactions.
Ovoj kapsul zdravila Temozolomide Teva 20 mg trde kapsule vsebuje tudi pomožno snov sončno rumeno FCF (E110), ki lahko povzroči alergijske reakcije.
The excipients (including adjuvants) listed in section 6.1 of the SPC are allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required.
Za pomožne snovi, navedene v poglavju 6.1 SPC , tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Pomožne snovi (vključno z dodatki), navedene v poglavju 6.1. SPC tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Pomožne snovi (vključno z dodatki), navedene v poglavju 6.1 SPC tabela 1 (dovoljene snovi) priloge Uredbi Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Pomožne snovi (vključno z dodatki), navedene v poglavju 6.1. SPC, so bodisi snovi, za katere tabela 1 priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Pomožne snovi (vključno z dodatki), navedene v poglavju 6.1. SPC, tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Za pomožne snovi (vključno z dodatki), navedene v poglavju 6.1. SPC tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excipients (including adjuvants) listed in section 6.1 of the SPC considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Pomožne snovi (vključno z dodatki) navedene v poglavju 6.1 SPC, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excipients listed in section 6.1 of the SPC (Glycerol formal and Macrogol 400) are allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required.
Za pomožne snovi, navedene v poglavju 6.1 SPC (glicerol formal in makrogol 400) , tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excipients listed in section 6.1 of the SPC are allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required.
Pomožne snovi, navedene v poglavju 6.1. SPC tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben.
The excipients listed in section 6.1 of the SPC are allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required.
Za pomožne snovi, navedene v poglavju 6.1 SPC , tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excipients listed in section 6.1 of the SPC are allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required.
Za pomožne snovi, navedene v poglavju 6.1 SPC , tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben.
The excipients listed in section 6.1 of the SPC are allowed substances for which table 1 of the annex to Commission Regulation (EU) No.
Za pomožne snovi, navedene v poglavju 6.1 SPC, tabela 1 (dovoljene snovi) Priloge Uredbe Komisije (EU) št.
The excipients listed in section 6.1 of the SPC are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Za pomožne snovi, navedene v poglavju 6.1 SPC kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo (ES) št.
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this product.
Za pomožne snovi, navedene v poglavju 6.1 SPC , tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this product.
Za pomožne snovi, navedene v poglavju 6.1 SPC, tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo (ES) št.
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Za pomožne snovi, navedene v poglavju 6.1 SPC , tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this product.
Za pomožne snovi, navedene v poglavju 6.1 SPC , tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Za pomožne snovi, navedene v poglavju 6.1 SPC , tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo (ES) št.
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Za pomožne snovi, navedene v poglavju 6.1 SPC , tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Za pomožne snovi, navedene v poglavju 6.1 SPC, tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this product.
Za pomožne snovi, navedene v poglavju 6.1 SPC , tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Za pomožne snovi, navedene v poglavju 6.1 SPC , tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required, or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Za pomožne snovi, navedene v poglavju 6.1 SPC , tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excipients, including adjuvants, listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this product.
Pomožne snovi (vključno z dodatki), navedene v poglavju 6.1. SPC tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št.
The excretion of filgrastim in milk has not been studied in animals.
Izločanja filgrastima v mleko pri živalih niso raziskali.
The excretion of nelarabine in milk has not been studied in animals.
Izločanja nelarabina v mleko pri živalih niso proučevali.
The excretion of pramipexole into breast milk has not been studied in women.
Izločanja pramipeksola v materino mleko niso raziskovali.
The excretion of ranolazine in milk has not been studied in animals.
Izločanja ranolazina v mleko pri živalih niso raziskovali.
The excretion of rFXIII drug substance in milk has not been studied in animals.
Izločanje zdravilne učinkovine rFXIII v mleku pri živalih ni raziskano.
The exenatide clinical trials data source comprises 18 placebo-controlled trials, 21 active comparator and 2 open-label trials.
Podatki kliničnih preskušanj eksenatida izvirajo iz 18 s placebom kontroliranih preskušanj, 21 preskušanj, v katerih je bila primerjava zdravilna učinkovina, in 2 odprtih preskušanj.
The existence and scope of the pregnancy register and details of how to enter patients in it.
Obstoj in obseg registra nosečnosti in podrobnosti o vnosu bolnikov vanj.
The existence and scope of the pregnancy register and details of how to enter patients into it.
Obstoj in obseg registra nosečnosti ter podatki, kako vključiti bolnice vanj.
The expected accumulation ratio was 1.1-fold following subcutaneous administration of 150 mg canakinumab every 12 weeks.
Po subkutani uporabi 150 mg kanakinumaba vsakih 12 tednov je bilo pričakovano razmerje kopičenja 1,1.
The expected adverse events would be those related to the pharmacodynamic profile of a dopamine agonist, including nausea, vomiting, hyperkinesia, hallucinations, agitation and hypotension.
Pričakovani neželeni učinki, vključno s slabostjo, bruhanjem, hiperkinezijo, halucinacijami, agitacijo in hipotenzijo, bi morali biti povezani s farmakodinamičnimi lastnostmi dopaminskih agonistov.
The expected benefit of treatment should be carefully weighed against the safety findings observed for children and adolescents in the clinical trials (see sections 4.8 and 5.1).
Pričakovano korist zdravljenja je treba skrbno pretehtati glede na znane izsledke iz kliničnih preskušanj glede varnosti zdravila pri otrocih in mladostnikih (glejte poglavji 4.8 in 5.1).
The expected depletions of B- and T-cells were observed in the pregnant mice but haematological effects were not assessed in foetuses.
Pri brejih miših so ugotovili pričakovano izčrpanje celic B in T, a hematoloških učinkov pri plodovih niso ocenili.
The expected immunological response may not be obtained after vaccination of immunosuppressed patients, e.g. patients on immunosuppressive therapy.
Cepljenje pri bolnikih z oslabljenim imunskim odzivom, npr. pri bolnikih z imunosupresivnim zdravljenjem, lahko ne vzbudi pričakovanega odziva.
The expected immunological response may not be obtained after vaccination of immunosuppressed patients.
Možno je, da pri bolnikih ki prejemajo imunosupresivno terapijo, po cepljenju ne dosežemo pričakovanega imunskega odziva.
The expected in vivo peak increase in factor X level expressed as IU/dL (or % of normal) can be estimated using the following formulae:
Pričakovani največji dvig ravni faktorja X in vivo, izražen v i.e./dl (ali v % običajne vrednosti) je mogoče oceniti s pomočjo naslednjih formul:
The expected pattern of events or symptoms following intentional or accidental overdose with Xadago would be those related to its pharmacodynamic profile: MAO-B inhibition with activity-dependent inhibition of Na+ channels.
Pričakovani vzorec dogodkov ali simptomov po namernem ali nenamernem prevelikem odmerjanju zdravila Xadago je povezan z njegovim farmakodinamičnim profilom: zaviranje MAO-B z zaviranjem Na+ kanalčkov, ki je odvisno od aktivnosti.
The experience in children is limited
Izkušnje pri otrocih so omejene.
The experience in children is limited, therefore no recommendation for treatment of paediatric patients with HYCAMTIN can be given (see section 5.1).
Izkušnje pri otrocih so nezadostne, zato ni mogoče dati priporočil za zdravljenje pediatričnih bolnikov s kapsulami HYCAMTIN (glejte poglavje 5.1).
The experience in children is limited, therefore no recommendation for treatment of paediatric patients with HYCAMTIN can be given (see sections 5.1 and 5.2).
Izkušnje pri otrocih so nezadostne, zato ni mogoče dati priporočil za zdravljenje pediatričnih bolnikov z zdravilom HYCAMTIN (glejte poglavji 5.1 in 5.2).
The experience in children is limited, therefore no recommendation for treatment of paediatric patients with Potactasol can be given (see sections 5.1 and 5.2).
Izkušnje pri otrocih so nezadostne, zato ni mogoče dati priporočil za zdravljenje pediatričnih bolnikov z zdravilom Potactasol (glejte poglavji 5.1 in 5.2).
The experience in children is limited, therefore no recommendation for treatment of paediatric patients with topotecan can be given (see sections 5.1 and 5.2).
Izkušenj pri otrocih je malo, zato ni mogoče dati priporočil za zdravljenje pediatričnih bolnikov s topotekanom (glejte poglavji 5.1 in 5.2).
The experience in children is limited, therefore no recommendation for treatment of paediatric patients with Topotecan Teva can be given (see sections 5.1 and 5.2).
Izkušnje pri otrocih so omejene, zato ni mogoče dati priporočil za zdravljenje pediatričnih bolnikov s topotekanom (glejte poglavji 5.1 in 5.2).
The experience in children is limited.
Izkušenj pri otrocih je malo.
The experience in paediatric patients is limited.
Izkušnje pri pediatričnih bolnikih so omejene.
The experience in patients who are severely immunocompromised, receiving immunosuppressive therapy, and patients with severe neutropenia is limited since this population was excluded from phase III trials.
Izkušnje pri bolnikih z zelo oslabljenim imunskim sistemom, bolnikih, ki prejemajo imunosupresivno zdravljenje in bolnikih s hudo nevtropenijo so omejene, ker je bila ta populacija izključena iz preskušanj faze III.
The experience in patients with severe hepatic impairment is insufficient to determine if dose adjustment is required..
Izkušnje pri bolnikih s hudo jetrno okvaro ne zadoščajo za ugotovitev, ali je potrebno prilagoditi odmerek.
The experience in the randomised, uncontrolled phase (year 2) of the ADVANCE study and in the 2 year safety extension study ATTAIN was consistent with the experience in the 1 year placebo-controlled phase of the ADVANCE study.
Izkušnje iz randomizirane, nekontrolirane faze (2. leto) študije ADVANCE in iz 2-letne varnostne podaljšane študije ATTAIN so bile skladne z izkušnjami iz 1-letne, s placebom kontrolirane faze študije ADVANCE.
The experience of OPTISON in severely ill patients is limited
Izkušnje s kontrastnim sredstvom OPTISON pri hudo bolnih bolnikih so omejene;
The experience of overdoses with Thymanax is limited but reported symptoms include pain in the upper part of the stomach, somnolence, fatigue, agitation, anxiety, tension, dizziness, cyanosis or malaise.
Izkušnje s prevelikim odmerjanjem zdravila Thymanax so omejene, poročali pa so o simptomih, kot so bolečine v zgornjem delu želodca, zaspanost, utrujenost, razdraženost, zaskrbljenost, napetost, omotica, cianoza in občutek slabosti.
The experience treating women older than 65 years is limited.
Izkušnje pri zdravljenju žensk, starejših od 65 let, so omejene.
The experience with dalbavancin in elderly is limited: 276 patients ≥ 75 years of age were included in the Phase 2/3 clinical studies, of which 173 received dalbavancin.
Izkušnje z dalbavancinom pri starejših so omejene: 276 pacientov, starih 75 let ali več, je bilo vključenih v fazo 2/3 kliničnih študij, od katerih jih je 173 prejelo dalbavancin.
The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1).
Izkušnje z uporabo imatiniba pri bolnikih MDS/MPD v povezavi s preureditvijo genov za PDGFR so zelo omejene (glejte poglavje 5.1).
The experience with lacosamide in elderly patients with epilepsy is limited.
Pri starejših bolnikih z epilepsijo so izkušnje z uporabo lakozamida omejene.
The expiration date and time have passed.
ta potekla datum in čas uporabnosti zdravila,
the expiration date has passed.
če je že pretekel datum izteka roka uporabnosti na napolnjenem injekcijskem peresniku.
the expiration date has passed; it has been frozen, even if it has now thawed (syringe only).
je rok uporabnosti že potekel, je bila zamrznjena, čeprav je bila pozneje odmrznjena (samo injekcijska brizga).
The expiration date refers to the last day of the month.
Dan izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
The expiry date can be found on the ORENCIA carton and on each syringe.
Datum izteka roka uporabnosti zdravila je naveden na škatli zdravila ORENCIA in na vsaki injekcijski brizgi.